Troglitazone improves endothelial dysfunction in patients with insulin resistance.
about
Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profileThiazolidinediones in patients with diabetes mellitus and heart failure : implications of emerging data.Late cardiovascular consequences of gestational diabetes mellitus.Insulin resistance as a contributor to myocardial ischaemia independent of obstructive coronary atheroma: a role for insulin sensitisation?The evolving role of inflammation in obesity and the metabolic syndrome.Impact of thiazolidinedione therapy on atherogenesis.Should all diabetic patients receive statins?Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.The vascular endothelium in diabetes--a therapeutic target?Novel therapies targeting vascular endothelium.Oral antidiabetic agents as cardiovascular drugs.Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease.Gene expression profiling of potential PPARgamma target genes in mouse aorta.Endothelial function impairment in chronic venous insufficiency: effect of some cardiovascular protectant agents.Hypoglycaemia is more frequent in type 2 diabetic patients with co-morbid vascular disease: an analysis of the DiaRegis registry.Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease.Insulin resistance and vessel endothelial function.
P2860
Q24318872-06AB5222-B680-42B9-A978-2B19902D8E26Q31073390-1D367086-B9F1-4DF0-80A6-7CCBE389383CQ33687575-F211E57B-B243-4490-BF43-DB7A3A041241Q35583166-12B71C06-415C-49B7-8CB4-8DA7AD5D24FBQ36016962-5F6FE202-031D-439F-8951-F3FD3ABEFD96Q36232378-986B425A-F9FA-413C-8C7E-869D9BAF541BQ36385133-CAA00E29-044F-4270-8143-FE43EC07807AQ36567768-8B96155C-BF19-4286-BF29-A95AE95E8618Q36673550-DAF997B5-478D-4103-805A-7AAD8E082B8DQ36684472-74648765-28A1-429E-A889-4CE7BF0B6086Q36697741-375F98EF-B0CF-40B6-BC27-DF4CD3CB7343Q36835841-F2FA1D66-93C9-4418-9225-907C1A5093B8Q38342990-A1B6D075-4843-4D51-AC11-120564FF5263Q46110639-2E4AFF6F-8766-47D7-BD10-081152FCA954Q46220548-C13F136C-924E-4795-9CED-C1763654727DQ51472462-278E494E-5DB2-42B7-BEAE-1A96B2AF7EA3Q51540941-F68B92C1-616A-43FC-9842-0CA27FB7DD47
P2860
Troglitazone improves endothelial dysfunction in patients with insulin resistance.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Troglitazone improves endothelial dysfunction in patients with insulin resistance.
@en
Troglitazone improves endothelial dysfunction in patients with insulin resistance.
@nl
type
label
Troglitazone improves endothelial dysfunction in patients with insulin resistance.
@en
Troglitazone improves endothelial dysfunction in patients with insulin resistance.
@nl
prefLabel
Troglitazone improves endothelial dysfunction in patients with insulin resistance.
@en
Troglitazone improves endothelial dysfunction in patients with insulin resistance.
@nl
P2093
P356
P1476
Troglitazone improves endothelial dysfunction in patients with insulin resistance.
@en
P2093
Sunayama S
Watanabe Y
Yamaguchi H
P304
P356
10.5551/JAT1994.7.159
P577
2000-01-01T00:00:00Z